• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/8/21 9:25:44 PM ET
    $JAN
    Get the next $JAN alert in real time by email
    SC 13G 1 jan-sc13g_012921.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     
    JanOne Inc.

    (Name of Issuer)

     

     
    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

    47089W104

    (CUSIP Number)

     
     
    January 29, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
      Page 2 of 8

     

    CUSIP No.    47089W104    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    190,476 Shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    190,476 Shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    190,476 Shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.9%

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

    (1)

     

    Based on 2,401,410 shares of Common Stock outstanding as set forth in the Issuer’s Prospectus Supplement 424(b)(5) dated January 29, 2021 filed with the Securities and Exchange Commission on February 2, 2021.

     

     
      Page 3 of 8

     

    CUSIP No. 47089W104    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    190,476 Shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    190,476 Shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    190,476 Shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.9%

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

    (1)   

    Based on 2,401,410 shares of Common Stock outstanding as set forth in the Issuer’s Prospectus Supplement 424(b)(5) dated January 29, 2021 filed with the Securities and Exchange Commission on February 2, 2021.

     

     
      Page 4 of 8

     

     

    CUSIP No. 47089W104    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    190,476 Shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    190,476 Shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    190,476 Shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.9%

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

    (1)   

    Based on 2,401,410 shares of Common Stock outstanding as set forth in the Issuer’s Prospectus Supplement 424(b)(5) dated January 29, 2021 filed with the Securities and Exchange Commission on February 2, 2021. 

     

     
      Page 5 of 8

     

     

    CUSIP No. 47089W104    

     

    Item 1(a).   Name of Issuer: JanOne Inc. (the “Issuer”)
         
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:   

    325 E. Warm Springs Road, Suite 102

    Las Vegas, Nevada 89119

         
         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57 Street, FL 20, New York, NY 10019
         
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.001 per share
         
         
    Item 2(e).   CUSIP Number: 47089W104
         

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
     
      Page 6 of 8

     

    CUSIP No. 47089W104    

     

           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);  
             
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);  
             
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);  
             
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);  
             
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).  
             

     

    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 2,401,410 shares of Common Stock outstanding as set forth in the Issuer’s Prospectus Supplement 424(b)(5) dated January 29, 2021 filed with the Securities and Exchange Commission on February 2, 2021.

     

     

     
      Page 7 of 8

     

    CUSIP No . 47089W104    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:

    February 8, 2021

     

     

     

     

    Altium Capital Management, LP

     

     

     

     

    By:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    CEO

     

     

     

     

    Altium Growth Fund, LP

     

     

     

     

    By: Altium Growth GP, LLC

     

    Its: General Partner

     

     

     

     

    Signature:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    Managing Member of Altium Growth GP, LLC

     

     

     

     

    Altium Growth GP, LLC

     

     

     

     

    By:

    /s/ Jacob Gottlieb

     

    Name:

    Jacob Gottlieb

     

    Title:

    Managing Member

     
      Page 8 of 8

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1:

    Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

     

     

    Get the next $JAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sandstrom Katherine M

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:51:17 PM ET
    $JAN

    SEC Form 3 filed by new insider Porter Tracy A

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:50:21 PM ET
    $JAN

    SEC Form 3 filed by new insider Patadia Ankit B.

    3 - Janus Living, Inc. (0002100805) (Issuer)

    3/20/26 6:48:16 PM ET
    $JAN

    $JAN
    SEC Filings

    View All

    SEC Form S-8 filed by JanOne Inc.

    S-8 - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 8:18:24 AM ET
    $JAN

    SEC Form CERT filed by JanOne Inc.

    CERT - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 6:14:23 AM ET
    $JAN

    SEC Form EFFECT filed by JanOne Inc.

    EFFECT - Janus Living, Inc. (0002100805) (Filer)

    3/20/26 12:15:09 AM ET
    $JAN

    $JAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: Senior Housing REIT Janus Living to Make Public Debut

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 20, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on March 20thMarkets are lower Friday morning after Israeli Prime Minister Benjamin Netanyahu said his country was assisting the U.S. in reopening the Strait of Hormuz.Janus Living (NYSE:JAN) will begin trading on the NYSE today and celebrates its IPO on-site this morning.Guardian Metal Resources CEO & Executive Director Olive

    3/20/26 8:55:00 AM ET
    $ICE
    $JAN
    Investment Bankers/Brokers/Service
    Finance

    Healthpeak Properties and Janus Living Announce Pricing of Upsized $840 Million Janus Living Initial Public Offering

    Healthpeak Properties, Inc. (NYSE:DOC) ("Healthpeak") and Janus Living, Inc. ("Janus Living") announced the pricing of Janus Living's upsized initial public offering ("IPO") of 42,000,000 shares of Janus Living Class A-1 common stock at a price to the public of $20.00 per share. In addition, Janus Living has granted the underwriters a 30-day option to purchase up to an additional 6,300,000 shares of its Class A-1 common stock at the initial public offering price, less the underwriting discount. Janus Living's Class A-1 common stock is expected to begin trading on the New York Stock Exchange on March 20, 2026 under the ticker symbol "JAN." The IPO is expected to close on March 23, 2026, subj

    3/19/26 4:35:00 PM ET
    $DOC
    $JAN
    Real Estate Investment Trusts
    Real Estate

    ALT5 Sigma Corporation Partners With Hashtag Influencer to Enable Cryptocurrency Payment Processing for Influencer Marketing

    LAS VEGAS, NV / ACCESSWIRE / January 15, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a prominent innovator in the cryptocurrency sector, is pleased to announce a partnership with Hashtag Influencer, an advanced AI-powered SocialFi platform. This collaboration aims to enhance the influencer marketing landscape by enabling influencers in the gig economy to seamlessly and compliantly accept cryptocurrency payments for advertising deals with brands through social media platforms such as Instagram, Facebook, YouTube, and LinkedIn."While much attention has been given to the adoption of blockchain by traditional institutions, collaborating with innovators such as Hashtag Influencer-a forthcoming A

    1/15/25 7:00:00 AM ET
    $ALTS
    $JAN
    Finance: Consumer Services
    Finance

    $JAN
    Leadership Updates

    Live Leadership Updates

    View All

    ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors

    LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"

    11/6/24 8:30:00 AM ET
    $ALTS
    $JAN
    Finance: Consumer Services
    Finance

    JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

    LAS VEGAS, June 26, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles in research, investment banking, and finance, notably and most recently as Managing Director and Head of Technology Investment Banking at PI Financial Corp. (Ventum Financial).

    6/26/24 7:30:00 AM ET
    $JAN

    JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board

    LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction.  Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby m

    6/15/21 10:15:00 AM ET
    $JAN

    $JAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    SC 13G/A - JanOne Inc. (0000862861) (Subject)

    8/24/23 4:30:55 PM ET
    $JAN

    SEC Form SC 13G filed by JanOne Inc.

    SC 13G - JanOne Inc. (0000862861) (Subject)

    3/27/23 9:00:21 AM ET
    $JAN

    SEC Form SC 13G/A filed by JanOne Inc. (Amendment)

    SC 13G/A - JanOne Inc. (0000862861) (Subject)

    2/11/22 6:07:45 AM ET
    $JAN

    $JAN
    Financials

    Live finance-specific insights

    View All

    JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

    -The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS, July 10, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisi

    7/10/24 8:30:00 AM ET
    $JAN

    JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

    The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be i

    1/10/23 8:30:00 AM ET
    $JAN

    JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder

    LAS VEGAS, Dec. 7, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).  The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides JanOne Inc. with an opportunity to identify new drugs to enhance TSPO activity, and by doing so, reducing craving for meth. This new strategy for treating MUD w

    12/7/21 9:00:00 AM ET
    $JAN